Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | GALK1 | P51570 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.33 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.33 |
| ▸ | GPR3 | P46089 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.31 |
| ▸ | PRKCB | P05771 | 1/20 | 0.30 |
| ▸ | PRKCA | P17252 | 1/20 | 0.30 |
| ▸ | FLT3 | P36888 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18565449 | 0.87 | TLR4 (0.31) | NTSR1 | |
| SCHEMBL18565461 | 0.87 | KMT2A (0.33) | GAAPKMCASP1GALK1BLM | |
| SCHEMBL18565389 | 0.87 | GPR3 (0.39) | GAAPKMCASP1GALK1BLM | |
| SCHEMBL18565452 | 0.86 | L3MBTL1 (0.35) | GAAPKMCASP1GALK1BLM | |
| SCHEMBL18565460 | 0.85 | NTSR1 (0.31) | GAAPKMCASP1GALK1BLM | |
| SCHEMBL18565424 | 0.85 | LMNA (0.33) | GAAPKMCASP1GALK1BLM | |
| SCHEMBL18588724 | 0.85 | — | — | |
| SCHEMBL18565493 | 0.82 | ALKBH5 (0.35) | PKMMAPT | |
| SCHEMBL18565388 | 0.79 | GPR3 (0.44) | GAAPKMCASP1GALK1BLM | |
| SCHEMBL18565451 | 0.78 | FLT3 (0.33) | GAAPKMCASP1GALK1BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10290815-B2 | Composition, compound, material for organic electroluminescence element, ink composition, organic electroluminescence element, and electronic device | IDEMITSU KOSAN CO., LTD. (JP) | 2019-05-14 | — | — | US | disclosed |
| US-20170062733-A1 | COMPOSITION, COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENCE ELEMENT, INK COMPOSITION, ORGANIC ELECTROLUMINESCENCE ELEMENT, AND ELECTRONIC DEVICE | IDEMITSU KOSAN CO., LTD. (JP) | 2017-03-02 | — | — | US | disclosed |
| US-20170062733-A1 | COMPOSITION, COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENCE ELEMENT, INK COMPOSITION, ORGANIC ELECTROLUMINESCENCE ELEMENT, AND ELECTRONIC DEVICE | IDEMITSU KOSAN CO., LTD. (JP) | 2017-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10290815-B2 | Composition, compound, material for organic electroluminescence element, ink composition, organic electroluminescence element, and electronic device | EED, BMI1, CD99 | GAA 3187/4885PKM 2810/4885CASP1 3024/4885 |
| US-20170062733-A1 | COMPOSITION, COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENCE ELEMENT, INK COMPOSITION, ORGANIC ELECTROLUMINESCENCE ELEMENT, AND ELECTRONIC DEVICE | EED, BMI1, CD99 | GAA 3187/4885PKM 2810/4885CASP1 3024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.